PubMed

Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.

Namba R, Young LJ, Maglione JE, McGoldrick ET, Liu S, Wurz GT, DeGregorio MW, Borowsky AD, MacLeod CL, Cardiff RD, Gregg JP.

Breast Cancer Res. 2005;7(6):R881-9. Epub 2005 Sep 13.PMID: 16280035 [PubMed - indexed for MEDLINE]Related articlesFree article

Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.

Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Künzer H, Lichtner RB, Nishino Y, Parczyk K, Sauer G, Gieschen H, Ulbrich HF, Schneider MR.

J Natl Cancer Inst. 2004 Feb 4;96(3):210-8.PMID: 14759988 [PubMed - indexed for MEDLINE]Related articlesFree article

Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.

Namba R, Young LJ, Abbey CK, Kim L, Damonte P, Borowsky AD, Qi J, Tepper CG, MacLeod CL, Cardiff RD, Gregg JP.

Clin Cancer Res. 2006 Apr 15;12(8):2613-21.PMID: 16638874 [PubMed - indexed for MEDLINE]Related articlesFree article

Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.

Zhang H, Stephens LC, Kumar R.

Clin Cancer Res. 2006 Mar 1;12(5):1479-86.PMID: 16533771 [PubMed - indexed for MEDLINE]Related articlesFree article

Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors.

Rose-Hellekant TA, Skildum AJ, Zhdankin O, Greene AL, Regal RR, Kundel KD, Kundel DW.

Cancer Prev Res (Phila Pa). 2009 May;2(5):496-502. Epub 2009 Apr 28.PMID: 19401525 [PubMed - indexed for MEDLINE]Related articles

Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice.

Wurz GT, Read KC, Marchisano-Karpman C, Gregg JP, Beckett LA, Yu Q, Degregorio MW.

J Steroid Biochem Mol Biol. 2005 Nov;97(3):230-40. Epub 2005 Sep 8.PMID: 16153821 [PubMed - indexed for MEDLINE]Related articles

Tamoxifen inhibition of estrogen receptor-alpha-negative mouse mammary tumorigenesis.

Medina D, Kittrell FS, Hill J, Shepard A, Thordarson G, Brown P.

Cancer Res. 2005 Apr 15;65(8):3493-6.PMID: 15833886 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ.

Gandhi A, Holland PA, Knox WF, Potten CS, Bundred NJ.

Cancer Res. 2000 Aug 1;60(15):4284-8.PMID: 10945643 [PubMed - indexed for MEDLINE]Related articlesFree article

Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast.

Holland PA, Knox WF, Potten CS, Howell A, Anderson E, Baildam AD, Bundred NJ.

J Natl Cancer Inst. 1997 Jul 16;89(14):1059-65.PMID: 9230888 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.

Hird RB, Chang A, Cimmino V, Diehl K, Sabel M, Kleer C, Helvie M, Schott A, Young J, Hayes D, Newman L.

Cancer. 2006 May 15;106(10):2113-8.PMID: 16596655 [PubMed - indexed for MEDLINE]Related articlesFree article

Molecular markers and therapeutic targets in ductal carcinoma in situ.

Boland GP, Knox WF, Bundred NJ.

Microsc Res Tech. 2002 Oct 1;59(1):3-11. Review.PMID: 12242692 [PubMed - indexed for MEDLINE]Related articles

Use of SERMs for the adjuvant therapy of early-stage breast cancer.

Wolff AC, Davidson NE.

Ann N Y Acad Sci. 2001 Dec;949:80-8. Review.PMID: 11795384 [PubMed - indexed for MEDLINE]Related articles

Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.

Detre S, Riddler S, Salter J, A'Hern R, Dowsett M, Johnston SR.

Cancer Res. 2003 Oct 1;63(19):6516-22.PMID: 14559845 [PubMed - indexed for MEDLINE]Related articlesFree article

Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.

Kurbel S.

Med Hypotheses. 2005;64(6):1182-7.PMID: 15823713 [PubMed - indexed for MEDLINE]Related articles

Breast cancer prevention with selective estrogen receptor modulators: a perspective.

Pritchard KI.

Ann N Y Acad Sci. 2001 Dec;949:89-98. Review.PMID: 11795385 [PubMed - indexed for MEDLINE]Related articles

Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.

Sengupta S, Jordan VC.

Adv Exp Med Biol. 2008;630:206-19. Review.PMID: 18637493 [PubMed - indexed for MEDLINE]Related articles

Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.

Johnston SR.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4376s-4387s; discussion 4411s-4412s. Review.PMID: 11916228 [PubMed - indexed for MEDLINE]Related articles

Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus.

Zheng H, Kangas L, Härkönen PL.

J Steroid Biochem Mol Biol. 2004 Feb;88(2):143-56.PMID: 15084346 [PubMed - indexed for MEDLINE]Related articles

Antiestrogens--tamoxifen, SERMs and beyond.

Dhingra K.

Invest New Drugs. 1999;17(3):285-311. Review.PMID: 10665480 [PubMed - indexed for MEDLINE]Related articles

Heterogeneity of mammary lesions represent molecular differences.

Namba R, Maglione JE, Davis RR, Baron CA, Liu S, Carmack CE, Young LJ, Borowsky AD, Cardiff RD, Gregg JP.

BMC Cancer. 2006 Dec 5;6:275.PMID: 17147824 [PubMed - indexed for MEDLINE]Related articlesFree article